A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report.

anti‐interleukin‐6 antibody case report diagnosis idiopathic multicentric Castleman disease siltuximab

Journal

Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 25 08 2023
revised: 12 09 2023
accepted: 19 09 2023
medline: 19 10 2023
pubmed: 19 10 2023
entrez: 19 10 2023
Statut: epublish

Résumé

Idiopathic multicentric Castleman disease (iMCD) is challenging to diagnose due to clinical similarities with other conditions, such as Still's disease. Once diagnosed, iMCD may be effectively managed with the anti-interleukin-6 antibody siltuximab. Here, we present the case of a 19-year-old Polish woman with persistent fever and enlarged lymph nodes and whose diagnosis remained inconclusive following initial clinical assessments and extensive laboratory analyses. The patient had subsequent complaints of joint pain and erythema which were suspicious of Still's disease and resolved with treatment with tocilizumab. Later, the progression of symptoms, such as lymphadenopathy, and elevated interleukin-6 levels were consistent with Castleman disease, leading to the diagnosis of idiopathic multicentric Castleman disease seven years after the patient first reported symptoms. Treatment with the anti-interleukin-6 antibody siltuximab resulted in complete symptom resolution and normalization of inflammatory parameters. No adverse events were reported due to treatment with siltuximab.

Identifiants

pubmed: 37854256
doi: 10.1002/ccr3.7981
pii: CCR37981
pmc: PMC10580699
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e7981

Informations de copyright

© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Br J Haematol. 2021 Nov;195(3):328-337
pubmed: 34340261
Blood. 2017 Mar 23;129(12):1646-1657
pubmed: 28087540
Blood. 2018 Nov 29;132(22):2323-2330
pubmed: 30487129
Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62
pubmed: 27062097
Blood. 2020 Apr 16;135(16):1353-1364
pubmed: 32106302
Mod Rheumatol. 2019 Mar;29(2):302-305
pubmed: 30285516
Blood. 2014 May 8;123(19):2924-33
pubmed: 24622327
Clin Adv Hematol Oncol. 2022 Sep;20(9):564-571
pubmed: 36125948
Blood. 2017 Mar 23;129(12):1658-1668
pubmed: 28100459
Case Rep Hematol. 2022 Mar 30;2022:1840589
pubmed: 35399163
Cancer. 1956 Jul-Aug;9(4):822-30
pubmed: 13356266
Nat Rev Dis Primers. 2021 Nov 25;7(1):84
pubmed: 34824298
Ther Adv Hematol. 2016 Dec;7(6):360-366
pubmed: 27904739
Autoimmun Rev. 2014 Jul;13(7):708-22
pubmed: 24657513
Oncologist. 2020 Nov;25(11):963-973
pubmed: 32852137
Oncotarget. 2015 Oct 6;6(30):30408-19
pubmed: 26327301
J Clin Exp Hematop. 2022;62(2):85-90
pubmed: 35768241
Blood. 2018 Nov 15;132(20):2115-2124
pubmed: 30181172
Lancet Oncol. 2014 Aug;15(9):966-74
pubmed: 25042199
Ther Adv Hematol. 2022 Mar 02;13:20406207221082552
pubmed: 35251585

Auteurs

Magdalena Strach (M)

Department of Rheumatology and Immunology, Faculty of Medicine Jagiellonian University Medical College Kraków Poland.

Piotr Kuszmiersz (P)

Department of Rheumatology and Immunology, Faculty of Medicine Jagiellonian University Medical College Kraków Poland.

Łukasz Chmura (Ł)

Department of Pathomorphology, Faculty of Medicine Jagiellonian University Medical College Kraków Poland.

Mariusz Korkosz (M)

Department of Rheumatology and Immunology, Faculty of Medicine Jagiellonian University Medical College Kraków Poland.

Classifications MeSH